Embracing diversity in clinical trials
At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Search
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Behavioral science to improve cattle well-being
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Partnership Boehringer Ingelheim Lifebit health data
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
GastroGard the first imported equine drug in China
GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
George Okafo
My career challenge at Boehringer Ingelheim by George Okafo. Read it now!
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Boehringer Ingelheim: Discover the app set to transform animal care in rural India
Learn about the app set to transform animal care in rural India. Women will be empowered and goat welfare will be promoted. From idea to app!
TwistPak Mixing platform for swine vaccines
TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA
Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
Boehringer Olaf Scholz break ground for innovation center
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site